Incyte Corp (INCY):企業の財務・戦略的SWOT分析

◆英語タイトル:Incyte Corp (INCY) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH40874FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:64
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥50,625見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Incyte Corp (INCY) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Incyte Corp (Incyte) is a biopharmaceutical company which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis as well as patients with polycythemia vera who are intolerant to hydroxyurea. Jakafi is distributed principally through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Norvatis) develops and commercializes ruxolitinib outside the US for hematologic and oncologic indications under the name Jakavi. The company’s pipeline portfolio encompasses drug indications targeted at the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, multiple tumor types, b-cell malignancies, solid tumors, glioblastoma, liver cancer and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

Incyte Corp Key Recent Developments

Feb 09,2021: Incyte reports 2020 fourth quarter and year-end financial results, provides 2021 financial guidance and updates on key clinical programs
Dec 31,2020: Incyte announces data from multiple programs within its oncology portfolio accepted for presentation at the AACR annual meeting 2021
Nov 09,2020: Data from Incyte’s Oncology Portfolio accepted for presentation at the Society for Immunotherapy of Cancer 2020 Annual Meeting
Nov 05,2020: Incyte reports 2020 third quarter financial results and provides updates on key clinical programs
Aug 04,2020: Incyte reports 2020 second quarter financial results and provides updates on key clinical programs

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Incyte Corp – Key Facts
Incyte Corp – Key Employees
Incyte Corp – Key Employee Biographies
Incyte Corp – Major Products and Services
Incyte Corp – History
Incyte Corp – Company Statement
Incyte Corp – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Incyte Corp – Business Description
Product Category: Iclusig
Performance
Product Category: Jakafi
Performance
Product Category: Jakavi Product Royalty Revenue
Performance
Product Category: Milestone and Contract Revenue
Performance
Product Category: Olumiant Product Royalty Revenue
Performance
Product Category: Pemazyre
Performance
Product Category: Tabrecta Product Royalty revenue
Performance
R&D Overview
Incyte Corp – Corporate Strategy
Incyte Corp – SWOT Analysis
SWOT Analysis – Overview
Incyte Corp – Strengths
Incyte Corp – Weaknesses
Incyte Corp – Opportunities
Incyte Corp – Threats
Incyte Corp – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Incyte Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 09, 2021: Incyte reports 2020 fourth quarter and year-end financial results, provides 2021 financial guidance and updates on key clinical programs
Dec 31, 2020: Incyte announces data from multiple programs within its oncology portfolio accepted for presentation at the AACR annual meeting 2021
Nov 09, 2020: Data from Incyte’s Oncology Portfolio accepted for presentation at the Society for Immunotherapy of Cancer 2020 Annual Meeting
Nov 05, 2020: Incyte reports 2020 third quarter financial results and provides updates on key clinical programs
Aug 04, 2020: Incyte reports 2020 second quarter financial results and provides updates on key clinical programs
Jul 14, 2020: Recently Awarded Project: Incyte 1703
May 14, 2020: Data from Incyte’s Oncology portfolio accepted for presentation at the ASCO and EHA virtual meetings
May 05, 2020: Incyte reports 2020 first quarter financial results and provides updates on key clinical programs
Apr 24, 2020: Incyte appoints Christine Lennon as General Manager, Incyte Biosciences Canada
Mar 26, 2020: Incyte Names New Member to Its Board of Directors
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Incyte Corp, Key Facts
Incyte Corp, Key Employees
Incyte Corp, Key Employee Biographies
Incyte Corp, Major Products and Services
Incyte Corp, History
Incyte Corp, Subsidiaries
Incyte Corp, Key Competitors
Incyte Corp, Ratios based on current share price
Incyte Corp, Annual Ratios
Incyte Corp, Annual Ratios (Cont...1)
Incyte Corp, Annual Ratios (Cont...2)
Incyte Corp, Interim Ratios
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Incyte Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Incyte Corp (INCY):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Canadian Utilities Ltd (CU):電力:M&Aディール及び事業提携情報
    Summary Canadian Utilities Ltd (CUL), an ATCO company, is an electric utility. The company carries out electricity and natural gas distribution and transmission operations. It constructs and maintains electrical transmission and distribution lines and has stakes in generating plants through subsidia …
  • Asseco Business Solutions SA (ABS):企業の財務・戦略的SWOT分析
    Asseco Business Solutions SA (ABS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Chugai Pharmaceutical Co Ltd (4519):製薬・医療:M&Aディール及び事業提携情報
    Summary Chugai Pharmaceutical Co Ltd (Chugai) is a subsidiary of Hoffmann-La Roche Ltd, which focuses on the research, development, manufacture, commercialization, import and export of the biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of cancer; bone an …
  • Epic Pharma LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Epic Pharma LLC (Epic Pharma), a subsidiary of Humanwell Healthcare (Group) Co Ltd is a drug development company that manufactures and develops generic prescription drugs. The company’s products include amlodipine besylate, citalopram, betaxolol, nicardipine hydrochloride, guanfacine hydroch …
  • Schneider Electric SE:企業のM&A・事業提携・投資動向
    Schneider Electric SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Schneider Electric SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • OBI Pharma Inc (4174):製薬・医療:M&Aディール及び事業提携情報
    Summary OBI Pharma Inc (OBI Pharma) is a biopharmaceutical company that develops therapies for the treatment of cancer and infectious diseases. The company’s products include adagloxad simolenin, an active immunotherapy which is intended for the treatment of metastatic breast cancer; and OBI-833, a …
  • ZAPPALLAS, Inc. (3770):企業の財務・戦略的SWOT分析
    ZAPPALLAS, Inc. (3770) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • JenaValve Technology Inc:医療機器:M&Aディール及び事業提携情報
    Summary JenaValve Technology Inc (JenaValve Technology), a subsidiary of JenaValve Technology GmbH, is a medical device company that develops and manufactures transcatheter aortic valve replacement (TAVR) systems for transapical and transfemoral implantation. The company’s TAVR system is an investig …
  • Fortum Corporation (FUM1V)-エネルギー分野:企業M&A・提携分析
    Summary Fortum Corporation (Fortum) is a clean energy company, which generates, distributes and sells heat and electricity. The company undertakes operation and maintenance of power plants; and offers energy-related services. Fortum's operational assets include hydropower plants, condensing power pl …
  • Snap-on Incorporated:戦略・SWOT・企業財務分析
    Snap-on Incorporated - Strategy, SWOT and Corporate Finance Report Summary Snap-on Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Cochin Shipyard Ltd (COCHINSHIP):企業の財務・戦略的SWOT分析
    Cochin Shipyard Ltd (COCHINSHIP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • R-Pharm:製薬・医療:M&Aディール及び事業提携情報
    Summary R-Pharm is a pharmaceutical company that manufactures and markets therapeutic drugs. The company offers drugs in areas of oncology, hematology, cardiology, immunology, and antibacterial and anti-viral diseases. It offers solutions on treatment of HIV-infection, organ transplantation, dissemi …
  • McKesson Corporation:企業の戦略・SWOT・財務情報
    McKesson Corporation - Strategy, SWOT and Corporate Finance Report Summary McKesson Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • UBM plc:企業のM&A・事業提携・投資動向
    UBM plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's UBM plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • US Physical Therapy Inc (USPH):企業の財務・戦略的SWOT分析
    US Physical Therapy Inc (USPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Consolidated Edison Company of New York Inc:企業の戦略的SWOT分析
    Consolidated Edison Company of New York Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • MCB Bank Ltd:企業の戦略・SWOT・財務情報
    MCB Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary MCB Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • SYNNEX Corp (SNX):企業の財務・戦略的SWOT分析
    SYNNEX Corp (SNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Eguana Technologies Inc. (EGT):企業の財務・戦略的SWOT分析
    Eguana Technologies Inc. (EGT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • LG Chem Ltd (051910):電力:M&Aディール及び事業提携情報
    Summary LG Chem Ltd (LG Chem) is a chemical manufacturer. It manufactures and markets petrochemicals, IT and electronic materials, and energy solutions. The company’s product portfolio comprises poly vinyl chloride (PVC), ethylene, propylene, butadiene, benzene, polarizer, glass substrate, semicondu …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆